[Infliximab]

Ann Dermatol Venereol. 2019 Jun-Jul;146(6-7):483-486. doi: 10.1016/j.annder.2019.04.013. Epub 2019 Jun 20.

[Article in French]

Authors

C Goujon¹, H Bachelez²; Groupe de recherche sur le psoriasis de la Société française de dermatologie

Affiliations

¹ Immunologie clinique, centre hospitalier Lyon-Sud, 165, chemin du Grand Revoyet, 69310 Pierre-Bénite, France. Electronic address: catherine.goujon@chu-lyon.fr.
² Service de dermatologie, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.

PMID: 31230775
DOI: 10.1016/j.annder.2019.04.013

No abstract available

MeSH terms

Contraindications, Drug
Dermatologic Agents / pharmacology*
Drug Monitoring
Female
Half-Life
Humans
Infliximab / pharmacology*
Maternal-Fetal Exchange
Pregnancy
Psoriasis / drug therapy

Substances

Dermatologic Agents
Infliximab